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Abstract: Young CBA/J mice were injected with kanamycin under varying 
schedules then exposed to noise in order to determine the boundary conditions 
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 Aminoglycosides are antibiotic drugs used in the treatment of diseases caused by Gram-
negative bacteria and tuberculosis.  These cost-effective drugs, which include gentamicin, 
tobramycin, streptomycin, neomycin, and kanamycin are currently applied clinically most 
frequently in underdeveloped countries, and in the most extreme cases of a life-threatening 
illness because of their potential ototoxicity.  Aminoglycosides are known for causing a loss in 
hearing sensitivity, vestibular function, or nephrotoxicity to those who are administered the drug 
(Guthrie, 2008).  In the inner ear, these drugs target cochlear outer hair cells (OHCs) and type I 
vestibular hair cells (Rybak &Whitworth, 2005).  This results in a bilateral sensory hearing loss, 
mostly affecting high frequencies due to damage of the hair cells in the basal turn of the cochlea 
(Guthrie, 2008).  
 
Mouse models in ototoxin research 
To gain a better understanding of the cellular mechanisms of aminoglycoside ototoxicity, 
it is helpful to study their affects in animal models.  Mice, in particular, are increasingly used as a 
model of human hearing.  The mouse cochlea is anatomically and physiologically similar to that 
of a human.  Mice also develop and age quickly, making it convenient to study critical and 
sensitive periods (Henry & McGinn, 1992).  According to Henry (1981), kanamycin's effects are 
similar in mice and humans with the majority of hair cell loss being in the basal turn of the 
cochlea.  The age of the animal, however, greatly influences sensitivity to ototoxic agents.  In an 
attempt to establish a critical period in mice for kanamycin ototoxicity, Saunders and Chen 




days in groups aged 6-9, 10-13, or 15-18 days, then sacrificed the mice 15 days post-injection for 
morphologic analysis.  Animals aged 10 to 13 days showed complete loss of OHCs throughout 
the cochlea while mice age 6-9 days only sustained damage to the OHCs in the basal turn.  
 Different strains of mice have shown different responses to kanamycin treatments.  The 
CBA/J mouse, in particular, has been shown to have greater threshold shifts after treated with 
kanamycin when compared to other strains, such as the C57BL/6 and NKCC1+/- (Chu et al., 
2006).  Mice in this study were aged to four weeks in an effort to establish a mouse model of 
ototoxicity past the “sensitive” period in developing mice.  They received daily kanamycin 
injections (700 mg/kg) subcutaneously for 14 consecutive days. Thresholds continued to worsen 
3 weeks post treatment (Chu et al., 2006).    Wu and colleagues (2001) used the same dosage of 
kanamycin as Chen and Saunders (1983) and injected different strains of mice twice daily for 10 
consecutive days.  They determined that BALBs are affected more sensitive to ototoxicity than 
the other strains of mice.  It should be noted that a greater dosage was necessary in these animals 
because they were considered adult animals. A kanamycin dose of 400 mg/kg i.p. daily for 10 
days was shown to produce threshold shift of 60-70 dB in developing mice (Sha et. al, 2001). 
  Adult animals are able to tolerate higher dosages of kanamycin without experiencing the 
same ototoxic effects that occur in their younger counterparts.  In a previous study, Henry and 
colleagues (1981) compared the affects of kanamycin in mice aged 13, 60, and 380 days.  They 
received two daily injections of kanamycin (500 mg/kg, i.p.) for two weeks.  Auditory function 
was assessed two days post treatment with electrocochleograms.  Results showed that the pre-
weanling mice had dramatic threshold shifts across all frequencies, while the older two groups of 




revealed an extensive OHC loss across the cochlea, while older mice only showed loss of OHCs 
in the basal turn.  The histological findings supported the electrocochleographic changes after 
kanamycin. 
 
Early window of heightened noise vulnerability 
 The pattern of cochlear damage caused by noise-induced hearing loss is also quite similar 
in mice and humans.  Cochlear noise injury is manifested as sensorineural hearing loss (SNHL), 
mostly affecting the higher frequencies.  Like ototoxicity, the consequences of noise exposure are 
age dependent.  An early study by Henry (1983) looked at the susceptibility of CBA/J mice to 
NIHL throughout their life span.  Mice were exposed to 124, 114, or 104 dB SPL of octave-band 
(12 to 24 kHz) noise for 5 minutes.  It was concluded that susceptibility in mice is greatest in a 
developmental window extending from 16-90 days of age.  Ohlemiller, Wright, and Heidbreder 
(2000) applied a noise dose response paradigm to young and old CBA/CaJ, C57BL/6J and 
BALB/J mice.  In that study, young (1-2 months old) and old (5-7 months old) mice were 
exposed to 110 dB of 4 to 45 kHz noise for varying durations.  Results confirmed that the 
younger mice are indeed more susceptible to noise.  Young CBA/CaJ mice, for example, had a 
NIPTS after a mere 3.42 minutes of noise exposure, while the older CBA/CaJs required roughly 
63 minutes to create the same probability of permanent threshold shifts.   
 
Interactions of simultaneous aminoglycosides and noise 
 Since the cellular targets of noise and ototoxic drugs are largely the same, it might be 




both animals and humans (Dayal et al., 1971; Quante, 1973; Dayal & Barek, 1975; Marques et 
al., 1975; Hawkins et al., 1975; Ryan & Bone, 1978; Brown et al., 1980 (as cited in Humes, 
1984); Brummett, Fox, & Kempton, 1992).  Gannon, Tso, and Chung (1979) examined the effect 
that impulse noise had on guinea pigs that had received a minimal dose of kanamycin (15 mg/kg 
vs. 50 mg/kg) and concluded that even when kanamycin alone does not cause any noticeable 
damage to hair cells, it can increase hair cells susceptibility to noise injury.  Brummett and 
colleagues (Brummett, Fox, & Kempton, 1992) injected guinea pigs with subclinical doses of 
kanamycin and exposed them to 45, 75, 95, or 115 dBA of noise for 7 days.  Again it was 
concluded that subclinical doses of kanamycin paired even with normally harmless levels of 
noise can cause permanent cochlear damage.  Most of these studies used guinea pigs or 
chinchillas as the animal model. 
 Recent experiments in young mice, however, have uncovered a protective effect of sub-
clinical doses of kanamycin (300 mg/kg) against NIHL.  In a recent study CBA/J mice 20 days 
old were injected every 12 hours for 10 consecutive days, then on day 11 were noise exposed to 
30 s of 110 dB SPL broad band noise.  While ABRs conducted 10 days post exposure showed 
substantial threshold shifts (~50 dB) in saline-treated control mice, the experimental mice (both 
noise and kanamycin) showed statistically normal thresholds (Baum, 2008).   
 
Purpose of the present study 
This novel finding created the need to determine the minimal amount of kanamycin that 
can be administered and still protect from noise injury.  Since there is little to no concurring 




understanding this phenomenon.  The boundaries of this particular event must be defined.  How 
few kanamycin doses can be given and still prevent NIHL?  The purpose of this study was to 
find just how infrequent injections of kanamycin can be administered and protection from noise 
exposure is still evident.   This was done by injecting kanamycin in young CBA/J mice at 
varying intervals (once daily, once every other day, and once every third day) for a span of 10 
days. 
 
MATERIALS AND METHODS 
Animals 
 A total of 24 CBA/J mice of either gender were used in this study.  All mice were housed 
in the Mechanisms of Cochlear Injury Laboratory at Washington University School of Medicine 
for 10 days while receiving treatment, and for the remainder of time were housed in the Central 
Institute for the Deaf Animal Colony.  All procedures were approved by the Animal Studies 
Committee at Washington University School of Medicine.  Animals were inspected for signs of 
otitis media.  Any animals with middle ear infection were excluded from the data analysis.   
 
Kanamycin 
 Mice were assigned to one of seven different treatment groups: kanamycin daily only, 
saline daily plus noise, kanamycin daily plus noise, kanamycin daily plus longer duration of 
noise, saline daily plus longer duration of noise, kanamycin every other day plus noise, and 
kanamycin every third day plus noise (see Table 1 below).  Mice that received kanamycin were 




kanamycin to yield 300 mg/kg per dose.  Injections were given between the hours of 7-9 AM.  
No mice died as result of the drug treatment. 
Treatment Group Number of Animals 
Kanamycin 1/day (no noise) 2 
Saline 1/day + 30 s noise 4 
Kanamycin 1/day + 30 s noise 6 
Kanamycin every other day + 30 s 
noise 6 
Kanamycin every 3rd day + 30 s noise 3 
Saline 1/day + 1.88 min noise 1 
Kanamycin 1/day + 1.88 min noise 2 
Table 1:  Number of animals per treatment group 
 
Noise Exposure 
 The majority of the mice assigned to a noise treatment group were exposed to 30 seconds 
of 110 dB SPL broadband noise (4-45 kHz).  This level and duration is the result of early noise-
dosing results in the previous study.  In keeping with prior studies, the initial hypothesis in the 
foundational study Baum (2008) was that subclinical kanamycin would act synergistically to 
produce substantial injury.  Thus the goal was to identify noise exposure durations (while fixing 
overall intensity) that produced little or no NIPTS.  Pilot exposures in young CBA/J, however, 
showed that exposures as brief as 0.5 minutes resulted in 100% of the mice exhibiting severe 
hearing loss.  An exposure duration of 4.0 min was originally selected for that study based upon 




minutes was sufficient enough in causing a NIPTS in 6 week old CBA/CaJ mice.  Because of the 
dramatic hearing loss created in pilot experiments, it was determined that a noise-dose response 
experiment needed to be conduced.  Rice, Gagnon, and Ohlemiller (2009) compared 6 week-old 
CBA/J and CBA/CaJ mice to find the 
threshold of duration in which NIPTS 
would be seen for each strain 
separately.  The conclusions of this 
study were that 0.90 minutes of noise 
was sufficient enough to cause 90% of 
the young CBA/Js to have a NIPTS, 
while 4.05 minutes was the length of 
duration that caused a similar loss in 
the CBA/CaJs.  It was decided that for 
this study, 30 seconds of noise would 
be reliably produce a NIPTS in young 
CBA/J mice.  It should be noted that 
this duration of noise produces more hearing loss in 30 day old CBA/J mice than suggested by 
Figure 1, presumably because the extent of noise vulnerability decreases between 30 days and 6 
wks of age. 
Figure 1: The proportion of young CBA/J and 
CBA/CaJ mice meeting the criterion for NIPTS.  The 
minimum NIPTS exposure for CBA/J (0.9 min) was 
clearly different from that in CBA/CaJ (4.05 min) 
Reprinted with permission from
   Rice, Gagnon, and Ohlemiller, 2009
Mice were placed in groups of two in a 21x21x11 cm wire cage surrounded by four 
speakers set at 0, 90, 180, and 360 degrees azimuth. This apparatus was housed within a single-




0.013 Hz throughout the exposure duration.    The noise was generated using General Radio 
1310 generators and filtered with Krohn-Hite 3550 filters.   Food and water were not accessible 
during the time of exposure.  Mice in a noise treatment group were exposed 15 minutes after 
final injections.  The rationale for this was previous evidence indicating that peak serum levels 
are reached approximately 15 minutes after administering kanamycin (cited in Wu et al., 2001). 
 
ABR Recordings 
 Auditory brainstem recordings were obtained ten days post treatment, or approximately 
40 days post gestation.  Animals in the kanamycin only group (no noise exposure) underwent  
ABR testing at 15 minutes post injection on day 10 (that is, at the time when noise exposure 
would occur), as well as 40 days post gestation. Animals were anesthetized using a ketamine and 
xylazine solution (80/15 mg/kg, i.p).  Subdermal needle electrodes were placed in the vertex, 
back, and behind the right pinna.  The animal's body temperature was kept at a constant 37.0 °C 
through the use of an isothermal pad and monitored via rectal probe.  Mice were positioned with 
their head's placed 7 cm from the speaker.  The base of the left ear was clamped with a small clip 
so that only the right side was stimulated.  Stimuli were presented 1000 times through the right 
speaker in 5 millisecond tonebursts at the following frequencies: 5, 10, 20, 28.3, and 40 kHz.  
Stimulus presentation and data acquisition utilized Tucker Davis Technologies System II 
hardware and software (BioSig 32).  Thresholds were defined as the lowest sound level (varied 
in 5 dB steps) that produced Wave I of the ABR. 
 After ABR thresholds were obtained for each frequency, mice were overdosed using 




solution.  The cochleae were harvested and placed in fixative.  Cochleae were later decalcified 
using an EDTA sodium solution, stained with Osmium, dehydrated using Acetone, and finally 
embedded in Epon-Araldite. 
 
RESULTS 
A two-way analysis of variance (ANOVA) was performed to in order to determine if there 
was any statistical significance in threshold differences between groups.  Among the seven 
different treatment groups, only two were 
found to have statistically significant 
differences in thresholds.  There was a 
clear difference between the ABR 
thresholds in animals who received 
kanamycin daily and 30 seconds of noise 
and those animals that received the same 
dosage of saline daily and noise (Figure 2).   
Animals that received saline daily for 10 
days had thresholds that were 30 to 40 dB greater than those animals in the kanamycin daily 
group.   
Figure 2:  Average thresholds for saline 1/day + 




Animals who received 
kanamycin every other day also showed 
statistically different thresholds when 
compared to the saline daily + noise 
group (Figure 3).  Majority of those 
within the kanamycin every other day 
group saw at least partial, if not 
complete, protection from 30 
seconds of noise.  There was little 
variation in between thresholds at all frequencies in all of the groups that received doses of 
kanamycin.  Animals that were injected daily with kanamycin and not exposed to noise showed 
no threshold shifts across all tested frequencies when compared to previous thresholds obtained 
at 30 days post-gestation directly following drug treatment. 
Figure 3: Saline 1/day + 30 s noise, KA every other day 
+ 30 s noise 
There were two animals who received daily injections of kanamycin for 10 days then 
were exposed to noise for 1.88 min.  One of the animals showed complete protection from even 
this duration of noise, while the other had substantially elevated thresholds.  A larger number 




 The purpose of this study was to determine the minimum applications of kanamycin that 




interactions previously reported.  Baum (2008) concluded that mice receiving twice daily doses 
of kanamycin plus noise exposure showed no significant average shifts in threshold compared to 
control groups.  The present results argue for the existence of a robust and easily established 
‘protected state’, such that even injections of kanamycin given every third day for ten days are 
sufficient to protect from NIHL. 
 
Subclinical kanamycin as a preconditioning stressor 
 Threshold preservation against noise by kanamycin may represent a form of 
preconditioning.  Preconditioning, as defined by Gagnon and colleagues (2007), refers to “the 
ability of a non-damaging or minimally damaging stressor to confer protection against the effects 
of a later and more injurious stressor”.   These investigators found that hypoxia prevents the 
exacerbation of NIHL in CBA mice when exposed to 90 minutes of broadband noise.  Yoshida 
and colleagues (1999) determined that heat stress preconditioning can also protect mice from 
NIHL.  An increase in heat shock proteins within the CBA/CaJ mouse cochlea created protection 
from 100 dB of octave band noise.   Other cellular processes that may underlie preconditioning 
are increased levels of glucocorticoid stress hormones and improved blood flow (Wang & 
Liberman, 2002). 
It is possible that the stress of handling mice alone is somewhat protective against noise 
exposure.  That is why one treatment group received saline daily prior to noise exposure.  Since 
the mice in that group had significant threshold shifts this factor could be ruled out in our results.  
Also, we included a treatment group that received only kanamycin daily with no noise exposure.  




kanamycin does not cause any hearing loss after 10 consecutive days of administration.  More 
recent findings have shown that a single dose of kanamycin, when administered 15 minutes prior 
to noise, is not enough to protect from NIHL (Baum, 2008).  These findings imply that the mere 
presence of kanamycin is not adequate to mediate protection.  Chronic treatment with kanamycin 
may be required to up-regulate protective mechanisms in the cochlea that prevent NIHL.  The 
minimum number of kanamycin injections that is protective was not addressed in this present 
study. 
There is little support of the protective nature of aminoglycosides in preventing NIHL in 
the literature.  This could be due to the fact that most of the studies that looked at the synergistic 
effects between kanamycin and noise were done with adult animals.  The protection may be seen 
only in the mouse and not in guinea pigs or chinchillas, which were the model of animals utilized 
in majority previous studies. Doses of kanamycin also varied widely among these studies as well.   
 
Clinical implications and future experiments 
 This study confirms the previous finding that kanamycin, when paired with noise in 
young CBA/J mice, can protect against NIHL  Identification of ‘boundary conditions’ for 
establishing the postulated protected state is important, as it should promote the discovery of the 
underlying cellular mechanisms.  Surprisingly, the present experiments actually produced little 
evidence of limits to the protection afforded by kanamycin.  More experimental conditions must 
therefore be tested.  Among the remaining unknowns is the question of how much noise can be 
protected against.  One group in the present study indicated that protection by kanamycin is not 




enough sample to determine the effectiveness of kanamycin protection.   
Further studies should address the generality of the present results both with regard to 
mouse strain and type of ototoxin that can elicit protection.  That young CBA/J mice are 
somehow unique in this regard cannot be ruled out, given the evidence presented here that these 
mice are phenomenally vulnerable to noise.  Investigations of this type may help establish 
whether there are specific genes that determine whether kanamycin protects–or worsens-noise 
injury in any individual. 
 It is truly paradoxical that a compound widely agreed to be highly toxic the inner ear as 
kanamycin can be protective.  The findings of this study bring about the possibility of using 
pharmaceuticals in the prevention of auditory damage.   There is a great need to find protective 
agents for those individuals who are exposed to recreational and occupational noise.   It is 
important to find the underlying protective mechanisms that kanamycin induces to prevent 
NIHL.  Further more, if the mechanisms of protection induced by kanamycin are discovered, 
alternative ways of up-regulating these pathways could be used to prevent cochlear damage and 
















Baum, E. A. (2008). Synergistic effects of noise, kanamycin, and hyperoxia on ABR thresholds 
in CBA/J mice. (Doctor of Audiology, Washington University School of Medicine). 
Retrieved from http://hdl.handle.net/1838/665  
 
Boettcher, F. A., Henderson, D., Gratton, M. A., Danielson, R. W., & Byrne, C. D. (1987). 
Synergistic interactions of noise and other ototraumatic agents. Ear and Hearing, 8(4), 192-
212.  
 
Brummett, R. E., Fox, K. E., & Kempton, J. B. (1992). Quantitative relationships of the 
interaction between sound and kanamycin. Archives of Otolaryngology - Head and Neck 
Surgery, 118(5), 498-500.  
 
Chu, H. -., Xiong, H., Zhou, X. -., Han, F., Wu, Z. -., Zhang, P., et al. (2006). Aminoglycoside 
ototoxicity in three murine strains and effects on NKCC1 of stria vascularis. Chinese 
Medical Journal, 119(12), 980-985. 
  
Gagnon, P. M., Simmons, D. D., Bao, J., Lei, D., Ortmann, A. J., & Ohlemiller, K. K. (2007). 
Temporal and genetic influences on protection against noise-induced hearing loss by 
hypoxic preconditioning in mice. Hearing Research, 226(1-2), 79-91.  
 
Gannon, R. P., Tso, S. S., & Chung, D. Y. (1979). Interaction of kanamycin and noise exposure. 
Journal of Laryngology and Otology, 93(4), 341-347. 
 
Guthrie, O. W. (2008). Aminoglycoside induced ototoxicity. Toxicology, 249(2-3), 91-96.  
 
Henry, K. R. (1983). Lifelong susceptibility to acoustic trauma: Changing patterns of cochlear 





Henry, K. R., Chole, R. A., McGinn, M. D., & Frush, D. P. (1981). Increased ototoxicity in both 
young and old mice. Archives of Otolaryngology, 107(2), 92-95.  
 
Henry, K. R., & McGinn, M. D. (1992). The mouse as a model for human audition. A review of 
the literature. Audiology, 31(4), 181-189.  
 
Hochman, J., Blakley, B. W., Wellman, M., & Blakley, L. (2006). Prevention of aminoglycoside-
induced sensorineural hearing loss. Journal of Otolaryngology, 35(3), 153-156.  
 
Humes, L. E. (1984). Noise-induced hearing loss as influenced by other agents and by some 
physical characteristics of the individual. Journal of the Acoustical Society of America, 
76(5), 1318-1329.  
 
Ohlemiller, K. K., Wright, J. S., & Heidbreder, A. F. (2000). Vulnerability to noise-induced 
hearing loss in 'middle-aged' and young adult mice: A dose-response approach in CBA, 
C57BL, and BALB inbred strains. Hearing Research, 149(1-2), 239-247.  
 
Rybak, L. P., & Ramkumar, V. (2007). Ototoxicity. Kidney International, 72(8), 931-935.  
 
Rybak Rice, M. E., Gagnon, P. M. & Ohlemiller, K. K. (2009, February 16) Divergence of noise-
induced hearing loss in CBA/J and CBA/CaJ mice. Poster presented at the 32nd Mid-Winter 
Meeting for the Association for Research in Otolaryngology, Baltimore, MD. 
 
Taleb, M., Brandon, C. S., Lee, F. -., Lomax, M. I., Dillmann, W. H., & Cunningham, L. L. 
(2008). Hsp70 inhibits aminoglycoside-induced hair cell death and is necessary for the 
protective effect of heat shock. JARO - Journal of the Association for Research in 
Otolaryngology, 9(3), 277-289.  
 
Wang, Y., & Liberman, M. C. (2002). Restraint stress and protection from acoustic injury in 
mice. Hearing Research, 165(1-2), 96-102.  
 
Wu, W. -., Sha, S. -., McLaren, J. D., Kawamoto, K., Raphael, Y., & Schacht, J. (2001). 
Aminoglycoside ototoxicity in adult CBA, C57BL and BALB mice and the sprague-dawley 





Yoshida, N., Kristiansen, A., & Liberman, M. C. (1999). Heat stress and protection from 




APPENDIX  A: Mean thresholds by treatment group 




































































































































APPENDIX C: ABR Data Log Form 
 
